OTHER INFORMATION
−Removed: None of our directors or officers have adopted , modified , or terminated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the three months ended March 31, 2026.
+Added: None of our directors or officers have adopted , modified , or terminated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the six months ended June 30, 2026.
The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Quarterly Report.
Description of Exhibit
−Removed: Certificate of Amendment to the Certificate of Incorporation of Acurx Pharmaceuticals, Inc.
−Removed: (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on September 22, 2025).
Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on April 16, 2026).
15 unchanged sentences
Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)
+Added: Filed herewith.
** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
1 unchanged sentence
Acurx Pharmaceuticals, Inc.
+Added: August 13, 2026
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 13, 2026
/s/ Robert G.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.